Author(s): Fiszman GL, Jasnis MA, Fiszman GL, Jasnis MA
Abstract Share this page
Abstract The epidermal growth factor receptor 2 (HER2) is a tyrosine kinase overexpressed in nearly 20\% to 25\% of invasive breast cancers. Trastuzumab is a humanized monoclonal antibody that targets HER2. The majority of patients with metastatic breast cancer initially respond to trastuzumab, however, within 1 year of treatment disease progresses. Several molecular mechanisms have been described as contributing to the development of trastuzumab resistance. They could be grouped as impaired access of trastuzumab to HER2, upregulation of HER2 downstream signaling pathways, signaling of alternative pathways, and impaired immune antitumor mechanisms. However, since many of them have overlapping effects, it would be of great clinical impact to identify the principal signaling pathways involved in drug resistance. Significant efforts are being applied to find other therapeutic modalities besides trastuzumab treatment to be used alone or in combination with current modalities.
This article was published in Int J Breast Cancer
and referenced in Journal of Cancer Science & Therapy